基因组分类器在个体化前列腺癌放射治疗中的应用:基于国际共识的系统综述与未来展望
该研究对放射治疗前列腺癌患者中基因组分类器(GC)的证据进行系统综述,并采用改良德尔菲法对31和30名国际多学科专家进行两轮调查,共识认为GC是改善原发及寡转移/转移患者风险分层的有前景工具,可能指导放疗野定义和治疗强化/降阶梯决策。
要点
- GC作为预测性生物标志物的证据主要来自术后放疗场景,作为预后标志物在根治性放疗中的验证正在涌现。
- 专家共识认为GC是改善原发和寡转移/转移患者风险分层的 promising 工具,可能指导放疗野定义和治疗决策。
- 47%的专家目前未在临床实践中使用GC,使用场景包括广泛转移(30%)、术后(27%)和新诊断(23%)。
核心结论
- 专家共识认为GC是改善原发和寡转移/转移前列腺癌患者风险分层的 promising 工具,可能指导放疗野定义和治疗强化/降阶梯决策。
- 该工作确认了GC的价值及GC在放疗场景中有前景的证据,期待更多GC作为预后标志物的研究,为未来预测能力研究奠定基础。
研究设计与样本
- 系统综述结合ClinicalTrials.gov在研临床试验筛选,并基于结果对国际多学科专家团队进行改良德尔菲法调查。
- 第一轮31名、第二轮30名专家分别作答,共识阈值定为≥75%同意的问题纳入定性综合。
主要发现
- GC作为预测性生物标志物的证据主要来自术后放疗场景,作为预后标志物在根治性放疗中的验证正在涌现。
- 专家在广泛转移(30%)、术后(27%)和新诊断(23%)患者中使用GC,47%的专家目前未在临床实践中使用GC。
关键数值与推荐
- 德尔菲调查中≥75%同意的问题被视为相关并纳入定性综合。
临床怎么用
- 专家共识认为GC是改善原发和寡转移/转移患者风险分层的 promising 工具,可能指导放疗野定义和治疗强化/降阶梯决策。
- 47%的专家目前未在临床实践中使用GC,使用场景包括广泛转移(30%)、术后(27%)和新诊断(23%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current risk-stratification systems for prostate cancer (PCa) do not sufficiently reflect the disease heterogeneity. Genomic classifiers (GC) enable improved risk stratification after surgery, but less data exist for patients treated with definitive radiation therapy (RT) or RT in oligo-/metastatic disease stages. To guide future perspectives of GCs for RT, we conducted (1) a systematic review on the evidence of GCs for patients treated with RT and (2) a survey of experts using the Delphi method, addressing the role of GCs in personalized treatments to identify relevant fields of future clinical and translational research. We performed a systematic review and screened ongoing clinical trials on ClinicalTrials.gov. Based on these results, a multidisciplinary international team of experts received an adapted Delphi method survey. Thirty-one and 30 experts answered round 1 and round 2, respectively. Questions with ≥75% agreement were considered relevant and included in the qualitative synthesis. Evidence for GCs as predictive biomarkers is mainly available to the postoperative RT setting. Validation of GCs as prognostic markers in the definitive RT setting is emerging. Experts used GCs in patients with PCa with extensive metastases (30%), in postoperative settings (27%), and in newly diagnosed PCa (23%). Forty-seven percent of experts do not currently use GCs in clinical practice. Expert consensus demonstrates that GCs are promising tools to improve risk-stratification in primary and oligo-/metastatic patients in addition to existing classifications. Experts were convinced that GCs might guide treatment decisions in terms of RT-field definition and intensification/deintensification in various disease stages. This work confirms the value of GCs and the promising evidence of GC utility in the setting of RT. Additional studies of GCs as prognostic biomarkers are anticipated and form the basis for future studies addressing predictive capabilities of GCs to optimize RT and systemic therapy. The expert consensus points out future directions for GC research in the management of PCa.
引用
- Spohn SKB, Draulans C, Kishan AU, et al. Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus. Int J Radiat Oncol Biol Phys. 2022. PMID: 36596346. doi:10.1016/j.ijrobp.2022.12.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。